Biontech Se

This large study is testing updated mRNA vaccines designed to protect against newer Omicron variants of COVID-19 in healthy children aged 6 months to 12 years. Over 4,000 participants will receive one or more doses depending on their age and vaccination history. Researchers are m…

This study tests a variant-adapted COVID-19 vaccine in about 5,240 healthy adults aged 50 to 64. Half receive the vaccine, half a placebo, to see if it safely prevents COVID-19 caused by new virus variants. The goal is to find out how well the updated shot works in this age group…

This study tests two experimental vaccines (BNT164a1 and BNT164b1) to see if they are safe and trigger an immune response against tuberculosis. About 500 healthy adults who have already received the BCG vaccine will receive three doses of either a vaccine or a placebo. The goal i…

This Phase 3 trial tests an updated COVID-19 vaccine (BNT162b2, 2025/2026 formulation) in 343 children aged 5 to 11 who have medical conditions that put them at high risk for severe COVID-19. All participants receive one dose and are monitored for about 6 months to check safety a…

This early-stage trial tests an mRNA vaccine called BNT163, designed to prevent genital herpes caused by HSV-2 and possibly HSV-1. About 318 healthy adults and people with recurrent genital herpes will receive the vaccine or a placebo. The main goal is to check safety and measure…

This study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …

This Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …

This study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …